» Articles » PMID: 2446734

Cancer Antigen 125, Tissue Polypeptide Antigen, Carcinoembryonic Antigen, and Beta-chain Human Chorionic Gonadotropin As Serum Markers of Epithelial Ovarian Carcinoma

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1988 Jan 1
PMID 2446734
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer antigen 125 (CA 125) is common to most epithelial ovarian tumors. Therefore, it is potentially a good marker of this disease. This hypothesis was evaluated by measuring the serum levels of CA 125 in 81 patients with ovarian cancer (25 with nonactive and 56 with active disease), in 105 patients of both sexes with nonovarian tumors, and in 171 healthy controls of both sexes. The serum levels of three other markers, tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), and human chorionic gonadotropin, beta subunit (beta-hCG), were also measured in the same 357 subjects. The results of this study clearly indicate the clinical irrelevance of both CEA and beta-hCG as tumor markers in ovarian carcinomas. Conversely, the clinical usefulness of CA 125 and TPA was confirmed. In particular, CA 125 and TPA showed comparable sensitivity, while CA 125 showed a higher specificity for ovarian cancer than TPA. The association of CA 125 with TPA was very useful in continuous observation of patients with active disease in order to evaluate the clinical effectiveness of the therapy. Moreover, for patients in clinical remission, the markers allowed early detection of a recurrence of the disease.

Citing Articles

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.

Eismann J, Heng Y, Waldschmidt J, Vlachos I, Gray K, Matulonis U J Cancer Res Clin Oncol. 2019; 146(2):503-514.

PMID: 31745703 PMC: 6985087. DOI: 10.1007/s00432-019-03078-9.


Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.

Abu Hassan S, Nielsen D, Tuxen M, Petersen P, Soletormos G Future Sci OA. 2017; 3(3):FSO216.

PMID: 28884012 PMC: 5583662. DOI: 10.4155/fsoa-2017-0023.


Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Fernandes L, Kim S, Saad S, Matos D World J Gastroenterol. 2006; 12(24):3891-4.

PMID: 16804977 PMC: 4087940. DOI: 10.3748/wjg.v12.i24.3891.


Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.

Fernandes L, Kim S, Matos D World J Gastroenterol. 2005; 11(5):645-8.

PMID: 15655814 PMC: 4250731. DOI: 10.3748/wjg.v11.i5.645.


Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.

Tuxen M, Soletormos G, Dombernowsky P Br J Cancer. 2001; 84(10):1301-7.

PMID: 11355938 PMC: 2363637. DOI: 10.1054/bjoc.2001.1787.